

Current Clinical Algorithms and Recent Therapeutic Advances in the Management of Multiple Myeloma and Related Blood Disorders (Video Program)

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- The IFM/DFCI 2009 trial evaluating lenalidomide/bortezomib/dexamethasone (RVD) induction therapy with or without autologous stem cell transplant (ASCT) demonstrated a significant improvement in both progression-free survival (PFS) and overall response rate for patients who received _____.
 - RVD
 - RVD + ASCT
 - Neither a nor b
- The ongoing Phase III TOURMALINE MM2 study is evaluating lenalidomide and dexamethasone with or without _____ for patients with newly diagnosed multiple myeloma (MM) who are not eligible for stem cell transplant.
 - Carfilzomib
 - Bortezomib
 - Ixazomib
- The Phase III SWOG-S0777 trial evaluating Rvd versus Rd for patients with newly diagnosed MM without intent for immediate ASCT demonstrated _____ with Rvd.
 - A significant improvement in PFS
 - No improvement in PFS
- The PAVO study presented by Usmani and colleagues at the 2016 ASH meeting suggested that daratumumab in combination with human hyaluronidase enzyme _____ safely be administered via subcutaneous injection.
 - Could
 - Could not
- Infusion reactions associated with administration of daratumumab tend to persist over the course of the patient's treatment.
 - True
 - False
- The Phase III POLLUX study evaluating lenalidomide and dexamethasone with or without daratumumab _____ a significant improvement in PFS with the addition of daratumumab for patients with relapsed or refractory MM.
 - Demonstrated
 - Did not demonstrate
- Which of the following categories reflects the mechanism of action of isatuximab?
 - Anti-CD38 monoclonal antibody
 - Anti-PD-1/PD-L1 antibody
 - Immunomodulatory drug (IMiD)
 - Proteasome inhibitor
- Sensitivity to venetoclax for MM has primarily been observed in patients with t(11;14) disease.
 - True
 - False
- Recent studies have demonstrated that the addition of pembrolizumab _____ successfully restore sensitivity to lenalidomide and/or pomalidomide in patients with IMiD-refractory MM.
 - Can
 - Cannot
- Results from the QuiRedex study indicated a benefit in time to disease progression for patients with _____ who received lenalidomide/dexamethasone versus observation.
 - Monoclonal gammopathy of undetermined significance
 - MM
 - Smoldering myeloma